Literature DB >> 28042646

Does parathyroid hormone control bone quality?

Dolores Shoback1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28042646     DOI： 10.1007/s12020-016-1222-0

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  10 in total

1.  Vertebral Fractures and Bone Mineral Density in Patients With Idiopathic Hypoparathyroidism on Long-Term Follow-Up.

Authors:  Himika Chawla; Soma Saha; Devasenathipathy Kandasamy; Raju Sharma; Vishnubhatla Sreenivas; Ravinder Goswami
Journal:  J Clin Endocrinol Metab       Date:  2017-01-01       Impact factor: 5.958

2.  The effect of adding PTH(1-84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study.

Authors:  Tanja Sikjaer; Lars Rejnmark; Lars Rolighed; Lene Heickendorff; Leif Mosekilde
Journal:  J Bone Miner Res       Date:  2011-10       Impact factor: 6.741

3.  Postsurgical hypoparathyroidism--risk of fractures, psychiatric diseases, cancer, cataract, and infections.

Authors:  Line Underbjerg; Tanja Sikjaer; Leif Mosekilde; Lars Rejnmark
Journal:  J Bone Miner Res       Date:  2014-11       Impact factor: 6.741

4.  Skeletal changes after restoration of the euparathyroid state in patients with hypoparathyroidism and primary hyperparathyroidism.

Authors:  Cristiana Cipriani; Alice Abraham; Barbara C Silva; Natalie E Cusano; Mishaela R Rubin; Donald J McMahon; Chengchen Zhang; Didier Hans; Shonni J Silverberg; John P Bilezikian
Journal:  Endocrine       Date:  2016-10-18       Impact factor: 3.633

Review 5.  Bone imaging in hypoparathyroidism.

Authors:  B C Silva; M R Rubin; N E Cusano; J P Bilezikian
Journal:  Osteoporos Int       Date:  2016-08-30       Impact factor: 4.507

6.  The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years.

Authors:  Mishaela R Rubin; John P Bilezikian; Donald J McMahon; Thomas Jacobs; Elizabeth Shane; Ethel Siris; Julia Udesky; Shonni J Silverberg
Journal:  J Clin Endocrinol Metab       Date:  2008-06-10       Impact factor: 5.958

7.  Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop.

Authors:  John P Bilezikian; Maria Luisa Brandi; Richard Eastell; Shonni J Silverberg; Robert Udelsman; Claudio Marcocci; John T Potts
Journal:  J Clin Endocrinol Metab       Date:  2014-08-27       Impact factor: 5.958

8.  Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study.

Authors:  Michael Mannstadt; Bart L Clarke; Tamara Vokes; Maria Luisa Brandi; Lakshminarayan Ranganath; William D Fraser; Peter Lakatos; Laszlo Bajnok; Roger Garceau; Leif Mosekilde; Hjalmar Lagast; Dolores Shoback; John P Bilezikian
Journal:  Lancet Diabetes Endocrinol       Date:  2013-10-07       Impact factor: 32.069

9.  Presentation of Hypoparathyroidism: Etiologies and Clinical Features.

Authors:  Dolores M Shoback; John P Bilezikian; Aline G Costa; David Dempster; Henning Dralle; Aliya A Khan; Munro Peacock; Marco Raffaelli; Barbara C Silva; Rajesh V Thakker; Tamara Vokes; Roger Bouillon
Journal:  J Clin Endocrinol Metab       Date:  2016-03-04       Impact factor: 5.958

10.  Increased vertebral morphometric fracture in patients with postsurgical hypoparathyroidism despite normal bone mineral density.

Authors:  Maira L Mendonça; Francisco A Pereira; Marcello H Nogueira-Barbosa; Lucas M Monsignore; Sara R Teixeira; Plauto Ca Watanabe; Lea Mz Maciel; Francisco Ja de Paula
Journal:  BMC Endocr Disord       Date:  2013-01-03       Impact factor: 2.763
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.